Cargando…
Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis
HIV continues to be one of the greatest challenges facing the global health community. More than 36 million people currently live with HIV and, in 2015 2.1 million new infections were reported globally. Pre-Exposure Prophylaxis (PrEP) prevents HIV infection by inhibiting viral entry, replication, or...
Autores principales: | Khandalavala, Karl, Mandal, Subhra, Pham, Rachel, Destache, Christopher J., Shibata, Annemarie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987555/ https://www.ncbi.nlm.nih.gov/pubmed/29881781 http://dx.doi.org/10.15436/2377-1372.17.1583 |
Ejemplares similares
-
Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis
por: Mandal, Subhra, et al.
Publicado: (2017) -
Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments
por: Perazzolo, Simone, et al.
Publicado: (2020) -
Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study
por: Mandal, Subhra, et al.
Publicado: (2022) -
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
por: Destache, Christopher J, et al.
Publicado: (2009) -
2501. CCR5 Targeted ARV Loaded Nanoparticle: Dual Protection for HIV Functional Cure
por: Destache, Christopher J, et al.
Publicado: (2019)